Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,564 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults

NCT06602531
View directory record Official record
Conditions
Influenza, Human
Interventions
ARCT-2304, Control vaccine younger adults, Control vaccine older adults, Placebo Vaccine
Biological · Other
Lead sponsor
Arcturus Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
La Mesa, California • San Bernardino, California • Longmont, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 9:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers

NCT00336102
View directory record Official record
Conditions
Breast Cancer, Fatigue, Hypothyroidism
Interventions
physiologic testing, fatigue assessment and management, management of therapy complications
Other · Procedure
Lead sponsor
University of South Florida
Other
Eligibility
20 Years to 80 Years · Female only
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
41
States / cities
Phoenix, Arizona • Greeley, Colorado • Loveland, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

NCT01346969
View directory record Official record
Conditions
Reduction in Hypertrophic Skin Scarring
Interventions
EXC 001
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Pasadena, California • Whittier, California • Lake Worth, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 25, 2026, 9:40 PM EDT
Not listed Not applicable Interventional

Chronicare for Type 2 Diabetes (Chronicare-T2D)

NCT03997331
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
CRx Health, Chronicare
Other
Lead sponsor
QuiO
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Midland, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Not applicable Interventional

Increasing HCV Linkage to Care Among People Who Inject Drugs

NCT04741750
View directory record Official record
Conditions
Hepatitis C
Interventions
Simplified HCV care within a mobile medical unit
Other
Lead sponsor
Family Health Centers of San Diego
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 25, 2026, 9:40 PM EDT
Enrolling by invitation Not applicable Interventional

Testing the Efficacy of ACT for Life

NCT04829682
View directory record Official record
Conditions
Suicide
Interventions
ACT for Life, Present Centered Therapy
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Battle Creek, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 25, 2026, 9:40 PM EDT
Terminated Phase 2 Interventional

NLA101 in Adults Receiving High Dose Chemotherapy for AML

NCT03301597
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
NLA101, Standard of Care (SOC) chemotherapy
Biological · Drug
Lead sponsor
Nohla Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms

NCT02163226
View directory record Official record
Conditions
Bone Metastases
Interventions
Hypofractionated Radiation Treatment, One Radiation Treatment, Questionnaire
Radiation · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Gilbert, Arizona • Voorhees Township, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 25, 2026, 9:40 PM EDT
Not yet recruiting Phase 3 Interventional

iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma

NCT07815574
View directory record Official record
Conditions
Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
Interventions
iSCIB1+, Nivolumab & Ipilimumab, Placebo
Biological · Drug · Other
Lead sponsor
Scancell Ltd
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

NCT03193190
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Duarte, California • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 25, 2026, 9:40 PM EDT
Withdrawn Phase 2 Interventional

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

NCT00753740
View directory record Official record
Conditions
Cancer, Ovarian Cancer, Solid Tumor
Interventions
IT-101 (12mg/m2/dose), IT-101 (15mg/m2/dose), 5% Dextrose (Placebo)
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years to 78 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Decatur, Illinois • Minneapolis, Minnesota • Brightwaters, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Not applicable Interventional

Interscalene Brachial Plexus Block Washout to Reverse Inadvertent Phrenic Nerve Blockade

NCT03677778
View directory record Official record
Conditions
Anesthesia, Local, Phrenic Nerve Paralysis, Upper Extremity Injury, Phrenic Nerve Palsy on the Left, Phrenic Nerve Palsy on the Right
Interventions
Normal saline injected via interscalene nerve catheter, Placebo
Procedure · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study in Refractory Behcet's Disease

NCT00995709
View directory record Official record
Conditions
Behcet Disease
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Arlington, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

NCT01706367
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
C. difficile vaccine, C. difficile vaccine +adjuvant
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Pembroke Pines, Florida • South Miami, Florida • Overland Park, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Phase 4 Interventional Results available

An Analysis of the Efficacy of a Pre-Emptive Multimodal Pain Regimen in Reducing Acute Post-Operative Pain and Narcotic Pain Medication Requirements in Spine Surgery

NCT04522206
View directory record Official record
Conditions
Pain, Postoperative, Spine Injuries and Disorders, Narcotic Use
Interventions
Pre-op Multimodal analgesia (MMA) regimen + standard post-op oxycodone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 25, 2026, 9:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)

NCT05776563
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Nutrition visits, Intensification of diabetes regimen, Continuous glucose monitor (CGM)
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

NCT01063829
View directory record Official record
Conditions
HCMV Reactivation or HCMV End-Organ Disease
Interventions
60 mg AIC246, 120 mg AIC246, 240 mg AIC246, Placebo
Drug · Other
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

NCT02311907
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions
Carboplatin, Glutathione, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
390
States / cities
Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 259 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Phase 1Phase 2 Interventional

T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza

NCT01728753
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Favipiravir
Drug
Lead sponsor
MDVI, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

NCT00358501
View directory record Official record
Conditions
Severe Hepatic Veno-Occlusive Disease
Interventions
Defibrotide
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
22
States / cities
Duarte, California • Palo Alto, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 25, 2026, 9:40 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
904 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
23
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Not applicable Interventional

IVF Clinical Trial of Two Different Treatment Protocols.

NCT00799929
View directory record Official record
Conditions
Infertility
Interventions
in vitro fertilization (IVF/ICSI)
Other
Lead sponsor
New Hope Fertility Center
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Phase 2 Interventional Results available

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

NCT03175367
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evinacumab, Matching placebo, Background Lipid Modifying Therapy (LMT)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 25, 2026, 9:40 PM EDT
Completed Phase 3 Interventional

Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media

NCT02044341
View directory record Official record
Conditions
Acute Otitis Media
Interventions
AR01, Glycerin ear drops
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
2 Months to 18 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
29
States / cities
Sheffield, Alabama • Tuscon, Arizona • Jonesboro, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 25, 2026, 9:40 PM EDT